Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: NLGP counterbalances the immunosuppressive effect of tumor-associated mesenchymal stem cells to restore effector T cell functions

Fig. 5

NLGP withdraws TC-MSC-mediated inhibition of cystathionase expression in DCs by regulating IL-10/STAT3 signaling pathway. a DCs were treated in vitro with normal MSC, TC-MSC, and NLGP-treated TC-MSC supernatant along with equal concentration of rIL-10, rIL-6, rVEGF, and rTGFβ respectively. Expression of cystathionase and β-actin mRNAs was analyzed by RT-PCR. Representative figures are presented from three independent experiments performed with the relative expression of target gene transcripts normalized against β-actin transcript levels as presented in bar diagrams. **p < 0.001 versus DCs cultured in the presence of NLGP-treated TC-MSC supernatant. b The expression of CD105+Vimentin+IL-10+ MSCs in tumors isolated from PBS and NLGP-treated tumor-bearing mice respectively is depicted in representative histogram. Gating strategy with FMO are shown in Additional file 1: Figure S1. c DCs were exposed to TC-MSC versus NLGP-treated TC-MSC culture supernatants and their expression levels of pSTAT3 and STAT3 were evaluated by western blot. Representative figures are presented from three different experiments. Mean relative expression of pSTAT3 and STAT3 are also presented in each group of DCs normalized against GAPDH. *p < 0.05; d DCs were pre-treated in vitro with stat3 siRNA before being exposed to TC-MSC as well as NLGP-treated TC-MSC supernatant and the expression levels of cystathionase and β-actin mRNA determined by RT-PCR. Representative figures are presented from three independent experiments performed with the relative expression of target gene transcripts normalized against β-actin mRNA as presented in bar diagram. *p < 0.05. ns = nonsignificant

Back to article page